Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) generates news across biotechnology, licensing, financing and corporate diversification activities. Company press releases highlight its evolution from a biotechnology focus into a diversified business with several divisions and an emphasis on becoming a revenue generating company. For followers of WINT news, this means updates can span drug development milestones, asset sales, licensing income opportunities, environmental services initiatives, fintech transactions and capital markets activity.
In the biotech arena, Windtree’s news flow has included interim data and scientific presentations for its cardiovascular drug candidate istaroxime and related SERCA2a activators, as well as decisions to adjust or terminate specific clinical studies based on resources and strategic priorities. The company has also reported on strengthening its patent estate for these cardiovascular assets and later announced an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC while retaining rights to a share of future proceeds and transferring certain development payables.
Windtree’s communications also cover its acute pulmonary franchise, where a global license agreement for RDS treatments such as SURFAXIN, lyophilized lucinactant and AEROSURF may generate milestone and royalty payments if development and commercialization progress under the licensee. Additional news items describe corporate strategy decisions, including a focus on environmental services and other revenue generating businesses, a letter of intent to acquire CommLoan, Inc. in the fintech and commercial real estate lending technology space, and the outcome of stockholder votes supporting financing flexibility.
Investors tracking WINT-related headlines will also see coverage of financing arrangements, preferred stock conversions, equity line of credit structures, and the company’s exploration of a BNB cryptocurrency treasury strategy, as well as its transition from the Nasdaq Capital Market to over-the-counter trading. Bookmarking this news feed can help readers monitor how Windtree’s mix of biotech assets, licensing agreements and diversified business initiatives evolves over time.
Windtree Therapeutics (NasdaqCM: WINT) announced positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock. The study met its primary endpoint, significantly improving systolic blood pressure over six hours compared to placebo. Significant benefits were also observed in many secondary endpoints.
The study evaluated two different dose regimens of istaroxime against placebo, with infusions lasting up to 60 hours. It focused on improving low blood pressure and heart function in SCAI Stage B cardiogenic shock patients. The safety profile was favorable and consistent with previous clinical trials.
Detailed results will be presented at the Heart Failure Society of America Meeting on September 30, 2024. Windtree plans to issue a press release with more detailed results and conduct an investor call following the presentation.
Windtree Therapeutics (NASDAQ: WINT) has completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime for early cardiogenic shock caused by heart failure. The study aims to extend positive results from a previous Phase 2 trial, evaluating istaroxime's ability to improve heart function and blood pressure. The trial includes longer dosing duration and dose tapering, with topline data expected in late September 2024.
Istaroxime is a novel first-in-class therapy that has shown promise in three Phase 2 trials for acute heart failure. The global cardiogenic shock market is estimated at $1.25 billion annually. The study, conducted in the U.S., Europe, and Latin America, focuses on dose optimization and further characterization of istaroxime's SERCA2a mechanism in early cardiogenic shock patients.
Windtree Therapeutics (NASDAQ: WINT) reported its Q2 2024 financial results and provided key business updates. The company expects to complete enrollment and report topline data for its Phase 2 SEISMiC Extension Study by Q3 2024 end. Windtree has begun enrollment in the Phase 2 SCAI Stage C cardiogenic shock study. In July 2024, the company closed two financial transactions for aggregate gross proceeds of $13.9 million. Windtree also entered a Common Stock Purchase Agreement with an equity line investor for up to $35 million. The company reported an operating loss of $11.5 million for Q2 2024, compared to $6.8 million in Q2 2023. As of June 30, 2024, Windtree had cash and cash equivalents of $1.8 million and current liabilities of $8.8 million, raising substantial doubt about its ability to continue as a going concern.
Windtree Therapeutics (NASDAQ: WINT) has announced significant changes to its board of directors, effective August 13, 2024. The company has appointed Saundra Pelletier and Jed Latkin as new independent directors, bringing extensive experience in public company leadership and the biotech industry. Pelletier, currently serving as Interim Chair and CEO of Evofem Biosciences, offers over 25 years of executive leadership experience. Latkin brings nearly three decades of financial and biotech expertise, including roles at ProPhase Labs and Navidea Biopharmaceuticals.
These appointments coincide with the resignations of Daniel Geffken and Leslie Williams from the board. Additionally, Mark Strobeck has been named Lead Independent Director. The company views these changes as strategic, particularly with upcoming Phase 2b clinical trial results and potential Phase 3 entry for its cardiovascular asset, istaroxime.
Windtree Therapeutics (NASDAQ: WINT) has provided an update on the clinical development of istaroxime, a novel first-in-class therapy for acute heart failure and early cardiogenic shock. The company is nearing completion of enrollment for its SEISMiC Extension Phase 2b study in early cardiogenic shock patients, with topline data expected by the end of the quarter. The study focuses on dose optimization and SERCA2a effects for Phase 3 planning.
Windtree is also progressing a parallel study in more severe SCAI Stage C cardiogenic shock patients. Additionally, the company has entered a license agreement with Lee's Pharmaceutical for the development and commercialization of istaroxime in Greater China, potentially worth up to $138 million in milestones plus royalties.
Windtree Therapeutics (NASDAQ: WINT) has closed a $12.9 million private placement of Series C Convertible Preferred Stock and warrants. The transaction includes $3.4 million in new funding and $9.5 million in debt cancellation. Additionally, the company established a $35 million equity line of credit.
The private placement involved issuing 16,099 shares of Series C Preferred Stock and warrants to acquire up to 3,440,631 additional common shares. The warrants have an exercise price of $4.11 per share and will become exercisable after six months.
Windtree plans to use the proceeds for working capital and general corporate purposes. The company is also nearing completion of its Phase 2b clinical trial for istaroxime in cardiogenic shock, with topline data expected by the end of the current quarter.
Windtree Therapeutics, a biotechnology company, regained compliance with Nasdaq's minimum bid price requirement after facing non-compliance due to its common stock price falling below $1 for 30 consecutive trading days. The company took necessary steps to meet the bid price threshold, resulting in compliance with the regulations.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
